Cheng Zhang

Cheng Zhang

Auto-generated profile, based on publicly available information

Cheng Zhang

MedStar Washington Hospital Center

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2023 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
RWRon Waksman
Ron Waksman
SBSukhdeep Bhogal
Sukhdeep Bhogal
PGPaul Gordon
Paul Gordon
AEAfshin Ehsan
Afshin Ehsan
SWSean R. Wilson
Sean R. Wilson
TRToby Rogers
Toby Rogers
Background: The LRT trial (Low-Risk Transcatheter Aortic Valve Replacement [TAVR]) demonstrated the safety and feasibility of TAVR in low-risk patients, with excellent 1- and 2-year outcomes. The objective of the current study is to provide the overall clinical outcomes and the impact of 30-day hypoattenuated leaflet thickening (HALT) on structural valve deterioration at 4 years. Methods: The prospective, multicenter LRT trial was the first Food and Drug Administration-approved investigational device exemption study to evaluate feasibility and safety of TAVR in low-risk patients with symptomatic severe tricuspid aortic stenosis. Clinical outcomes and valve hemodynamics were documented annually through 4 years. Results: A total of 200 patients were enrolled, and follow-up was available on 177 patients at 4 years. The rates of all-cause mortality and cardiovascular death were 11.9% and 3.3%, respectively. The stroke rate rose from 0.5% at 30 days to 7.5% at 4 years, and permanent pacemaker implantation rose from 6.5% at 30 days to 11.7% at 4 years. Endocarditis was detected in 2.5% of the cohort, with no new cases reported between 2 and 4 years. Transcatheter heart valve hemodynamics remained excellent post-procedure and were maintained (mean gradient 12.56±5.54 mm Hg and aortic valve area 1.69±0.52 cm 2 ) at 4 years. At 30 days, HALT was observed in 14% of subjects who received a balloon-expandable transcatheter heart valve. There was no difference in valve hemodynamics between patients with and without HALT (mean gradient 14.94±5.01 mm Hg versus 12.3±5.57 mm Hg; P =0.23) at 4 years. The overall rate of structural valve deterioration was 5.8%, and there was no impact of HALT on valve hemodynamics, endocarditis, or stroke at 4 years. Conclusions: TAVR in low-risk patients with symptomatic severe tricuspid aortic stenosis was found to be safe and durable at 4 years. Structural valve deterioration rates were low irrespective of the type of valve, and the presence of HALT at 30 days did not affect structural valve deterioration, transcatheter valve hemodynamics, and stroke rate at 4 years. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02628899.

4 February 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
WAWaiel Abusnina
Waiel Abusnina
IMIlan Merdler
Ilan Merdler
MCMatteo Cellamare
Matteo Cellamare
KCKalyan R. Chitturi
Kalyan R. Chitturi
ACAbhishek Chaturvedi
Abhishek Chaturvedi
BCBrian C. Case
Brian C. Case
Background: Coronary microvascular dysfunction (CMD), which mimics symptoms of obstructive coronary artery disease, has significant prognostic implications. While epicardial adipose tissue normally has a protective role, increased epicardial adipose tissue is associated with inflammation and may contribute to CMD. However, a direct correlation remains unclear. We aimed to investigate this association. Methods and Results: The CMDR (Coronary Microvascular Disease Registry) is a prospective, 2‐center registry that is enrolling patients with angina and nonobstructive coronary artery disease who underwent invasive hemodynamic assessment of the coronary microvasculature. Patients with chest computed tomography within 1 year of CMD evaluation were included. We measured epicardial fat volume (EFV) and calculated the EFV index. Logistic regression analysis was used to investigate the association between EFV and EFV index to CMD. Our study included 130 CMDR patients with associated chest CT; 35 were diagnosed with CMD. The CMD‐negative patients were younger than the CMD‐positive patients (58.52±11.97 versus 63.37±9.56 years; P =0.033), with numerically fewer women (64.2% versus 74.3%; P =0.279). Univariate regression analysis demonstrated a statistically significant association between EFV index and CMD diagnosis (odds ratio, 1.037 [95% CI, 1.014–1.063]; P =0.003), while no significance was observed for EFV (odds ratio, 1.006 [95% CI, 0.995–1.017]; P =0.292). Conclusions: Our results suggest a strong association between EFV index (a significant risk factor) and the presence of CMD. Future studies involving larger cohorts are needed to confirm the association of epicardial adipose tissue with CMD and investigate therapeutic targets to prevent CMD. Registration: URL: https://www.clinicaltrials.gov ; unique identifier: NCT05960474.

1 November 2020 in The American Journal of Cardiology
Verified
Journal Article
Closed access
AMAnees Musallam
Anees Musallam
CCChava Chezar-Azerrad
Chava Chezar-Azerrad
RTRebecca Torguson
Rebecca Torguson
BCBrian C. Case
Brian C. Case
CYCharan Yerasi
Charan Yerasi
RWRon Waksman
Ron Waksman

9 May 2022 in The American Journal of Cardiology
Verified
Journal Article
Closed access
GMGiorgio A. Medranda
Giorgio A. Medranda
TRToby Rogers
Toby Rogers
BCBrian C. Case
Brian C. Case
CZCheng Zhang
Cheng Zhang
CSCorey Shea
Corey Shea
RWRon Waksman
Ron Waksman

1 August 2021 in Cardiovascular Revascularization Medicine
Verified
Journal Article
Closed access
GMGiorgio A. Medranda
Giorgio A. Medranda
HFHooman Fazlalizadeh
Hooman Fazlalizadeh
BCBrian C. Case
Brian C. Case
CYCharan Yerasi
Charan Yerasi
CZCheng Zhang
Cheng Zhang
RWRon Waksman
Ron Waksman

1 July 2021 in The American Journal of Cardiology
Verified
Journal Article
Closed access
CCChava Chezar-Azerrad
Chava Chezar-Azerrad
AMAnees Musallam
Anees Musallam
CSCorey Shea
Corey Shea
CZCheng Zhang
Cheng Zhang
RTRebecca Torguson
Rebecca Torguson
RWRon Waksman
Ron Waksman